Once you start a patient on a TKI for the treatment of chronic myeloid leukemia, you want to monitor them very closely. There are several studies that show that patients who are monitored every 3 months during the first 2 years have better outcomes. During that first important milestone at 3 months, we want to see that the PCR has dropped below 10% on the international scale. Why do we pick 10% at 3 months? Because data from London and from Germany have suggested that patients who are above 10% in 3 months have inferior survival. So a patient who is not meeting this early milestone must be considered somewhat more high risk, we may want to even change therapy.For more information on managing your patients with CML, and to participate in an interactive case study in which you’ll be able to make clinical decisions for a patient with CP-CML, please view the activity available here.